Carcinoembryonic Antigen Market Outlook - 2030
Carcinoembryonic antigen (CEA) is a substance found on the surface of some cells. It is a type of glycoprotein produced by cells of the gastrointestinal tract during embryonic development. It is produced in very small amounts after birth. The level of CEA in the bloodstream is relatively low unless certain diseases - including certain forms of cancer - are present so CEA level test is done in bloodstream to check cancer of the colon and rectum and also other cancers such as that of the pancreas, stomach, breast, lung, and medullary carcinoma of the thyroid and ovarian cancer. CEA is as a tumour marker, especially for cancers of the gastrointestinal tract. CEA is most frequently tested in blood. It can also be tested in body fluids and in biopsy tissue. Before a tumour is removed from the body CEA pre and post-surgery test is done.
Covid-19 Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the carcinoembryonic antigen market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Trends and Application:
Carcinoembryonic antigens are glycoproteins that play a major role in cell adhesion. Carcinoembryonic antigen is present at very low concentration in healthy adults. Normal carcinoembryonic antigen level in healthy adult is in range between 2.5-5.0 µg/L. Level up may increase due to benign disease or smoking. However, its concentration in serum rise very high in some types of cancer. Hence, carcinoembryonic antigen used as a marker and assist in monitoring the treatment of various malignant and non-malignant conditions. As, sensitivity and specificity are low the test is more useful for monitoring than diagnosis. Carcinoembryonic antigen detection test often carried out after the surgery to identify percent of carcinoembryonic antigen level. In humans, carcinoembryonic antigen family consist of overall 29 genes, in which 18 are normally expressed.
Global carcinoembryonic antigen market segmented based on application of carcinoembryonic antigen: malignant condition and non-malignant condition. Malignant condition further subdivided into colorectal carcinoma, gastric carcinoma, pancreatic carcinoma, lung carcinoma, breast carcinoma, ovarian cancer, thyroid cancer and others. Furthermore, non-malignant condition subdivided into chronic kidney disease, pancreatitis, inflammatory bowel disease, irritable bowel syndrome, and others.
Drivers:
Increase number of cancer patients:
Cancer is considered to be the second major cause of death globally, about 70% of deaths occur from cancer in rural areas. Every year there is an increase in cancer diagnosed leading to minimally diagnostic procedures and increasing per capita healthcare expenditure, hence driving the market growth upwards. Tobacco use and alcohol use is the most prominent risk factor for cancer and is accountable for approximately 22% of cancer deaths. Resulting in need for CEA test in the market
Increase in geriatric population:
The geriatric population is more prone to chronic disease conditions, technology advancement and, government initiatives relating to cancer awareness by a non-profit organization such as Cancer Prevention and Control Research Network (CPCRN) are driving the growth of the market. CEA appears to be the most cost-effective test for the detection of potentially curable recurrent disease.
Restrains:
- Lack of awareness about the CEA test and failure to detect cancer at the initial stage and threat of infections by CEA testing are restraining the carcinoembryonic antigen market growth.
- CEA is not an effective screening test for hidden (occult) cancer since early tumors may not cause significant blood elevations. Also, many tumors never cause an abnormal blood level, even in advanced disease. Because there is variability between results obtained between laboratories, the same laboratory should do repeat testing when monitoring a patient with cancer.
Key Market developments:
Some of the major players operating in global carcinoembryonic antigen market include Abbott Diagnostics, Correlogic Systems, Inc., GenWay Biotech Inc., Quest Diagnostics, and Roche Diagnostics. The market is highly consolidated, and hence companies are engaged in mergers and acquisitions. Manufacturer face continuous pressure to introduce new technology with more sensitivity in the market.
- In April 2019, Kitov Pharma developed the first-in-class combination oncology therapies.
- In February 2019, Redpath Integrated Pathology launched a new, patent-pending, customized test to accurately measure carcinoembryonic antigen (CEA) in all pancreatic cyst fluids.
Key benefits of the report:
- This study presents the analytical depiction of the global Carcinoembryonic antigen industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Carcinoembryonic antigen market share.
- The current market is quantitatively analyzed from to highlight the global Carcinoembryonic antigen market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Carcinoembryonic antigen market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Carcinoembryonic Antigen Market research report:
- What are the leading market players active in the Carcinoembryonic antigen market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Carcinoembryonic Antigen Market Report Highlights
| Aspects | Details |
 By Detected Cancer Type |
|
 By Test Type |
|
 By End Users |
|
 By Region |
|
 Key Market Players | F. Hoffmann-La Roche Ltd, Correlogic Systems, Inc., Omega Diagnostics Group PLC, Creative Diagnostics, Boster Biological Technology, RayBiotech, Inc., GenWay Biotech Inc., Abbot, Quest Diagnostics |
Loading Table Of Content...
